Archive


Category: $5.25B

  • PerkinElmer to Acquire BioLegend for $5.25B

    Shots: PerkinElmer to acquire BioLegend for ~$5.25B in cash and stock transaction. The acquisition is expected to close by the end of 2021 The acquisition will allow PerkinElmer to build its growth in areas such as clinical diagnostics and food safety testing With the acquisition, BioLegend’s San Diego, California-based campus will become the global center […]